Inhibitors targeting hepatocyte growth factor receptor and vascular endothelial growth factor receptor tyrosine kinases

Expert Opinion on Therapeutic Patents

Volumn 16, Issue 5, 2006, Pages 713-718

  Cui, Jean ^a  

^a PFIZER INC   (United States)

Author keywords

c Met; Hepatocyte growth factor receptor (HGFR); Hepatocyte growth fator (HGF); Invasion; Kinase insert domain containing receptor (KDR); Lymphocyte specific protein tyrosine kinase (Lck); Metastasis; Proliferation; Receptor tyrosine kinase (RTK); Scatter factor (SF); Vascular endothelial growth factor (VEGF) receptor

Indexed keywords

BEVACIZUMAB; ERLOTINIB; GEFITINIB; IMATINIB; K 252A; LAPATINIB; N [4 [(6,7 DIMETHOXY 4 QUINOLYL)OXY] 3 FLUOROPHENYL] N' (PHENYLACETYL)THIOUREA; PHA 665752; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SCATTER FACTOR RECEPTOR; SCATTER FACTOR RECEPTOR TYROSINE KINASE INHIBITOR; SORAFENIB; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR TYROSINE KINASE INHIBITOR; XL 880;

ARTERIOSCLEROSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; COLON CARCINOMA; DRUG BIOAVAILABILITY; DRUG INDICATION; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; GASTROINTESTINAL STROMAL TUMOR; GENE TARGETING; HEART INFARCTION; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; NONHUMAN; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION;

EID: 33646696588     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.16.5.713     Document Type: Article

References (15)

1. MANNING G, WHYTE DB, MARTINEZ R, HUNTER T, SUDARSANAM S: The protein kinase complement of the human genome. Science (2002) 298:1912-1934.
2. KLEBL BM, MILLER G: Second-generation kinase inhibitors. Expert Opin. Ther. Targets (2005) 9(5):975-993.
3. COOPER CS, PARK M, BLAIR DG et al.: Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature (1984) 311:29-33.
4. PARK M, DEAN M, COOPER CS et al.: Mechanism of Met oncogene activation. Cell (1986) 45:895-904.
5. MAULIK G, SHRIKHANDE A, KIJIMA T, MA PC, MORRISON PT, SALGIA R: Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Cytokine Growth Factor Rev. (2002) 13:41-59.
6. MA PC, MAULIK G, CHRISTENSEN J, SALGIA R: c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev. (2003) 22:309-325.
7. JEFFERS M, SCHMIDT L, NAKAIGAWA N et al.: Activating mutations for the met tyrosine kinase receptor in human cancer. Proc. Natl. Acad. Sci. USA (1997) 94:11445-11450.
8. OTSUKA T, JAKUBCZAK J, VIEIRA W et al.: Disassociation of Met-mediated biological responses in vivo: the natural hepatocyte growth factor/ scatter factor splice variant NK2 antagonizes growth but facilitates metastasis. Mol. Cell Biol. (2000) 20:2055-2065.
9. MATSUMOTO K, NAKAMURA T: NK4 (HGF-antagomst/angiogenesis inhibitor) in cancer biology and therapeutics. Gann Manogr. Cancer Res. (2004) 52:125-139.
10. BURGESS T, COXON A, MEYER S et al.: Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors. Cancer Res. (2006) 66(3):1721-1729.
11. BARDELLI A, LONGATI P, WILLIAMS TA, BENVENUTI S, COMOGLIO PM: A peptide representing the carboxyl-terminal tail of the Met receptor inhibits kinase activity and invasive growth. J. Biol. Chem. (1999) 274:29274-29281.
12. MOROTTI A, MILA S, ACCORNERO P, TAGLIABUE E, PONZETTO C: K252a inhibits the oncogenic properties of Met, the HGF receptor. Oncogene (2002) 20:1692-1703.
13. CHRISTENSEN JG, SCHRECK R, BURROWS J et al.: A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antimutor activity in vivo. Cancer Res. (2003) 63(21):7345-7355.
14. HOV H, UTNE HOLT R, BAADE RØ T et al.: A selective c-Met inhibitor blocks an autocrine hepatocyte growth factor growth loop in ANBL-6 cells and prevents migration and adhension of myeloma cells. Clin. Cancer Res. (2004) 10(10):6686-6694.
15. LURUSSO P, APPLEMAN L, HEATH E et al.: A Phase I study of a novel spectrum kinase inhibitor (SSKI), XL-880, administrated orally in patients with solid tumors. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications, Philadelphia, PA, USA (14-18 November, 2005) A245.